AbbVie's $69 Billion Debt Load Is Hiding in a Forward P/E That Looks Cheap

Start with Humira. The asset was once a $20 billion annual revenue franchise. Biosimilar competition in the US (which started in early 2023) has eroded the franchise at the pace AbbVie management modelled, but the earnings leverage of the erosion has been more material than the revenue decline alone would suggest. Humira historically carried gross margin north of 90% and contributed disproportionately to operating income. Biosimilar substitution has moved significant volume to lower-margin Skyrizi and Rinvoq, which are excellent drugs but do not yet replicate Humira's profit contribution.

The second issue is the balance sheet. AbbVie spent heavily on M&A to pre-build the post-Humira portfolio, most notably Allergan for $63 billion in 2020 and Cerevel for $8.7 billion in 2024. The M&A has brought high-quality assets (Botox, neurology pipeline, ImmunoGen's elahere) but it has also loaded the balance sheet with debt at terms that now look less favourable in a higher-rate environment. The $69 billion of debt requires roughly $3.5-4.0 billion of annual interest expense, which is a direct offset to net income.

Third, the pipeline density is real but the timing of the revenue ramp is backloaded. Skyrizi and Rinvoq are growing fast, combined revenue likely crossed $25 billion in 2025 and is heading to $30 billion-plus by 2027. That growth is impressive. But it is also already in consensus numbers. The stock is not cheap because the revenue growth is under-modelled; it is cheap (if you believe it is) because the earnings bridge is hard.

Fourth, biosimilar competition is not a one-Humira event. The next wave will hit multiple myeloma and oncology products through 2027-2028. The pricing power that AbbVie has historically exercised is structurally more contested than it was a decade ago, and the pipeline replacement cycle has to keep delivering or the earnings gap widens.

Historically, large-cap pharma names that have managed through patent cliffs have needed 5-7 years to fully recover earnings power. Pfizer post-Lipitor, Merck post-Singulair, Novartis post-Diovan. The pattern is that the stock typically re-rates lower through the cliff transition, then slowly re-rates higher as the replacement portfolio matures. AbbVie is roughly three years into the Humira transition. There is more to come.

AbbVie's $69 billion of debt includes roughly $25 billion coming due in the next three years. Refinancing this stack at current market rates is materially more expensive than the original coupon structure. A 200 basis point uplift on $25 billion of refinancing is $500 million of incremental annual interest expense, which is a direct reduction to net income and to dividend coverage.

The dividend is covered comfortably on FCF terms; the $17.82 billion of 2025 FCF supports the roughly $10 billion of annual dividend payments. But the coverage on net income is now only 1.4x, which is the tightest it has been in over a decade. Any meaningful operational setback puts the dividend coverage into the warning zone, at which point the equity re-rates negatively.

The counter, that AbbVie can always refinance at favourable terms because it is investment-grade, is partly true. But the cost of capital is no longer the backdrop of 2020-2021. Refinancing pressure is a real margin drag that the bullish commentary is not modelling carefully.